Shares of Cadila Healthcare rose by nearly 5 per cent today after Zydus Cadila received the final nod from US health regulator to market Metoprolol Succinate extended-release tablets, used for treatment of various cardiac conditions, in the American market.
The stock jumped 4.78 per cent to end at Rs 387.65 on BSE. Intra-day, it soared 5.28 per cent to Rs 389.50.
On NSE, shares of the company gained 4.52 per cent to close at Rs 387.10.
In terms of equity volume, 1.50 lakh shares of the company were traded on BSE and over 45 lakh shares changed hands at NSE during the day.
The product will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said in a statement.
The company has received "final approval from the United States Food and Drug Administration (USFDA) to market Metoprolol Succinate extended-release tablets USP in the strengths of 25 mg, 50 mg, 100 mg and 200 mg", it said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
